Damien Anderson

Amplify.LA does not invest in hardware, clean technology, biotechnology, service-based business (i.e. no consulting ideas), physical goods, movies or other creative projects, and small markets. The firm prefers investing in social, mobile, consumer internet, SaaS, digital media, B2B, B2C, D2CD2C and technology.

Atlas has invested in over 150 life sciences startups since it began investing in the sector in 1990. Atlas invests in a range of therapeutic areas, including immuno-oncology, autoimmunity/inflammation, neuroscience, gene/cell therapy and editing, and anti-infectives. The current portfolio includes gene/cell editing/therapy companies AVROBIO, Generation Bio, Intellia Therapeutics, Obsidian Therapeutics, and Unum Therapeutics; oncology companies Bicycle Therapeutics, Kyn Therapeutics, Replimune, Surface Oncology, and Unum Therapeutics; autoimmunity companies Nimbus TherapeuticsNimbus Therapeutics and Padlock Therapeutics; anti-infectives company Spero Therapeutics; synthetic biology company Synlogic; RNA companies miRagen Therapeutics and Translate Bio; and CNS companies Cadent Therapeutics, Disarm Therapeutics, Navitor, and Rodin Therapeutics; and novel platform companies Accent Therapeutics, Kymera Therapeutics, Gemini Therapeutics, HotSpot Therapeutics, and Akero. Notable prior exits from Atlas’ life sciences portfolio include Actelion, Adnexus Therapeutics, Alnylam Pharmaceuticals, Annovation Biopharma, Annovation Biopharma, ArQule, Arrow Therapeutics, Arteaus Therapeutics, Avila Therapeutics, CoStim Pharmaceuticals, Crucell, deCODE genetics, Delinia, Exelixis, IFM Therapeutics Inc., Micromet, Momenta Pharmaceuticals, MorphoSys, Nimbus Apollo, Novexel, Padlock Therapeutics, Stromedix, and U3 Pharma.

Induction of the GATA6GATA6 transcription factor has resulted in formation of the three human germ layers, symmetry breaking and triggered differentiation of endoderm and mesoderm tissue types. GATA6-engineered cells self-organize and self-produce signaling cues for tissue morphogenesis. Synthetic biology approaches could be used to design gene circuits with specific features to induce certain tissue types such and perhaps induce angiogenesis or innervation into organoids.

Atlas has invested in over 150 life sciences startups since it began investing in the sector in 1990. Atlas invests in a range of therapeutic areas, including immuno-oncology, autoimmunity/inflammation, neuroscience, gene/cell therapy and editing, and anti-infectives. The current portfolio includes gene/cell editing/therapy companies AVROBIO, Generation Bio, Intellia Therapeutics, Obsidian Therapeutics, and Unum Therapeutics; oncology companies Bicycle Therapeutics, Kyn Therapeutics, Replimune, Surface Oncology, and Unum Therapeutics; autoimmunity companies Nimbus Therapeutics and Padlock Therapeutics; anti-infectives company Spero Therapeutics; synthetic biology company Synlogic; RNA companies miRagen Therapeutics and Translate Bio; and CNS companies Cadent Therapeutics, Disarm Therapeutics, Navitor, and Rodin Therapeutics; and novel platform companies Accent Therapeutics, Kymera Therapeutics, Gemini Therapeutics, HotSpot TherapeuticsHotSpot Therapeutics, and Akero. Notable prior exits from Atlas’ life sciences portfolio include Actelion, Adnexus Therapeutics, Alnylam Pharmaceuticals, Annovation Biopharma, Annovation Biopharma, ArQule, Arrow Therapeutics, Arteaus Therapeutics, Avila Therapeutics, CoStim Pharmaceuticals, Crucell, deCODE genetics, Delinia, Exelixis, IFM Therapeutics Inc., Micromet, Momenta Pharmaceuticals, MorphoSys, Nimbus Apollo, Novexel, Padlock Therapeutics, Stromedix, and U3 Pharma.

• ExplorerExplorer - a health and wellness product to understand the role that food and lifestyle can play in wellness.

Ople is an AI company located in Silicon ValleySilicon Valley, that accelerates the data science process so that data scientists can focus on the business at hand. Ople's Artificial Intelligence platform solves data science problems, and incorporates and replicates the behavior and best practices of other data scientists. The AI is used to accelerate data science, continuously optimizing algorithms and outcomes to reduce deployment time.

• Intelligent Logistics and Supply Chain: The AI learns from historical data to identify patterns in inventory, operations, and supply chain managementsupply chain management and recommend the course of action in a given scenario.

The KroniKare system is claimed to help early detection of complications like infection, undermining and problems with circulation. Artificial intelligenceArtificial intelligence and thermal imaging are used in their system which automates the assessment and management of chronic wounds. KroniKare is developing a mobile phone app that patients can use to make a five second video of their wounds. The wounds are analysed by the app in 30 seconds.

Neurobit’s technology aims to improve sleep quality and efficiency. Neurobit provides sleep records, which can normally take 1.5-2.5 hours for an expert technologist to manually score for one night of sleep. The company has a scorer called NEO based on 30,000 + polysomnography (PSG) data from 4000+ subject. Scoring is real-time and the system is offered as a cloud based Open RESTful API service. The Z3Score framework used by the company was developed in the laboratory of scientific advisor Dr. Michael Chee at the Cognitive Neuroscience Laboratory at Duke-NUS Medical School, SingaporeSingapore.

Altos Ventures has had 16 exits. The firm's most notable exits include Piqora, OutsparkOutspark, and OtherInbox. The firm has raised a total of $324.9M across 6 funds, one of them being Altos Ventures Korea Opportunity Fund II. This fund was announced on Mar 16, 2016, and raised a total of $110M.

On October 16, 2013 G1 Therapeutics completed their series A funding round with $12.5 million in funding from MedImmune VenturesMedImmune Ventures (lead investor), Mountain Group Capital, and Hatteras Venture Partners.